Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
$28.34
-$0.50(-1.51%)
At close: 4:00 PM EST
$28.34
-$0.50(-1.51%)
Day’s Range― - ―
52-Week Range$9.90 - $34.29
Previous CloseN/A
Volume140.31K
Average Volume (3M)814.59K
Market Cap
$2.95B
Enterprise Value$2.14B
Total Cash (Recent Filing)$874.65M
Total Debt (Recent Filing)$50.69M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 12, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding102,206,570
10 Day Avg. Volume1,087,693
30 Day Avg. Volume814,586
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue30.19
Enterprise Value/Gross Profit30.33
Enterprise Value/Ebitda-6.40
Forecast
1Y Price Target
$41.70Price Target Upside47.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.79
Revenue Forecast (FY)$74.55M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsREVEAL‑1 Phase 3 readout for elegrobart is a primary stock driver; positive efficacy and tolerability supporting monthly subcutaneous dosing could expand access and enlarge the treated patient population.
Commercial AdoptionSolid physician awareness and expressed interest in prescribing veligrotug and elegrobart improve the probability of rapid uptake upon approval and support commercial revenue potential.
RegulatoryFDA Priority Review for veligrotug accelerates the pathway to potential U.S. approval and could enable a timely commercial launch that materially boosts valuation, analyst notes.
Bears Say
Clinical RiskA weaker-than-expected efficacy readout or emergence of safety issues in REVEAL‑1 would pose significant downside risk and could prompt a steep re-rating of the stock.
Financing RiskLimited cash runway increases reliance on regulatory approvals, milestone payments, and early commercial performance, elevating financing risk if milestones are delayed or uptake is slower than expected.
Product CannibalizationAdoption of the long‑acting subcutaneous VRDN‑003 could cannibalize veligrotug sales, reducing expected incremental revenue and complicating peak sales forecasts.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $9.90 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $2.95B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 66 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Feb 26, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.98 by -$0.1.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -1.04.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 102,206,570 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.98. Following the earnings report the stock price went up 1.9%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.70 (47.14% Upside)
$41.70 (47.14% Upside)
Hedge Fund Trend
Increased
By 891.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.56%
12-Months-Change
Fundamentals
Return on Equity
-47.40%
Trailing 12-Months
Asset Growth
-0.57%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Stock 12 Month Forecast
Average Price Target
$41.70
▲(47.14% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.13% Insiders
25.71% Mutual Funds
14.85% Other Institutional Investors
40.04% Public Companies and Individual Investors